Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI115314

Interleukin 2 mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells.

R A Brooimans, A P Stegmann, W T van Dorp, A A van der Ark, F J van der Woude, L A van Es, and M R Daha

Department of Nephrology, University Hospital, Leiden, The Netherlands.

Find articles by Brooimans, R. in: PubMed | Google Scholar

Department of Nephrology, University Hospital, Leiden, The Netherlands.

Find articles by Stegmann, A. in: PubMed | Google Scholar

Department of Nephrology, University Hospital, Leiden, The Netherlands.

Find articles by van Dorp, W. in: PubMed | Google Scholar

Department of Nephrology, University Hospital, Leiden, The Netherlands.

Find articles by van der Ark, A. in: PubMed | Google Scholar

Department of Nephrology, University Hospital, Leiden, The Netherlands.

Find articles by van der Woude, F. in: PubMed | Google Scholar

Department of Nephrology, University Hospital, Leiden, The Netherlands.

Find articles by van Es, L. in: PubMed | Google Scholar

Department of Nephrology, University Hospital, Leiden, The Netherlands.

Find articles by Daha, M. in: PubMed | Google Scholar

Published August 1, 1991 - More info

Published in Volume 88, Issue 2 on August 1, 1991
J Clin Invest. 1991;88(2):379–384. https://doi.org/10.1172/JCI115314.
© 1991 The American Society for Clinical Investigation
Published August 1, 1991 - Version history
View PDF
Abstract

Previous reports have suggested the production of complement components C4, C2, and factor B by renal tissue. However, the cells involved in production of complement have not been identified. In this study metabolic labeling experiments demonstrated that human proximal tubular epithelial cells (PTEC) synthesize a 180-kD precursor of C3 that is secreted after proteolytic cleavage into a disulphide linked two-chain molecule as found in plasma. C3 present in culture supernatants of PTEC was functionally active, however, during the culture period there was a partial inactivation of the C3 molecule as assessed by hemolytic titration. Recombinant IL-2 enhances the rate of C3 synthesis in a dose-dependent manner reaching maximal stimulation at doses of 200-400 U/ml IL-2. Northern blot analysis demonstrated a 5.2-kb C3 mRNA species present in PTEC that was increased within 24 h of IL-2 treatment. IL-2-induced enhancement of C3 production by PTEC could be neutralized with specific antibodies to IL-2. This study demonstrates that C3 synthesis in PTEC is upregulated by IL-2, the major cytokine produced by activated T cells.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 379
page 379
icon of scanned page 380
page 380
icon of scanned page 381
page 381
icon of scanned page 382
page 382
icon of scanned page 383
page 383
icon of scanned page 384
page 384
Version history
  • Version 1 (August 1, 1991): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts